After a strong first half for biotech in 2026, the market pause in the third quarter is likely to extend through year-end ...
Cardiovascular drug developers are trying to undo in a few years the effects of pathways that have shaped disease over a lifetime. A series of late-stage ...
Treatments for rare diseases accounted for six of the nine NMEs CDER approved in September, including the first approved therapies for MCT8 deficiency and ...
A small group of specialist biotechs is advancing antifungals that could expand treatment options for invasive fungal ...
Brain shuttle technology is entering a new phase. A year after BioCentury mapped a field led by protein therapeutics, much of ...
At Jefferies in New York this June, Albert Bourla, CEO and chairman of Pfizer, piqued my interest. He said: “The way I see it ...
RougeTx believes restoring blood vessel stability could offer a better way to treat hereditary hemorrhagic telangiectasia ...
Earlier-stage and more modality-diverse China-origin assets are attracting multibillion-dollar licensing deals, ...
YolTech has evidence that rebuts Beam’s accusations that it misappropriated trade secrets, Emma Wang, the scientist who is ...
Three deals in the last week underscore a shift in pharma’s China partnering toward a wider range of therapies — and ...
The fate of uniQure’s Huntington disease gene therapy is once again in the balance, with four-year data raising fresh ...
Revier is targeting class IIa histone deacetylases (HDACs), whose enzymatic activity is mostly dormant in healthy cells but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results